Recent searches
    Trending searches
    ABBV logo AbbVie +
    AbbVie
    +
    Revenue breakdown by Products & Services
    Revenue breakdown by Geography

    AbbVie's Revenue by Segment

    In fiscal year 2024, AbbVie's revenue by segment (products & services) are as follows:

    • Alphagan/Combigan: $248.00 M
    • Botox Cosmetic: $2.72 B
    • Botox Therapeutic: $3.28 B
    • Duodopa: $447.00 M
    • H U M I R A: $8.99 B
    • Imbruvica: $3.35 B
    • Juvederm Collection: $1.18 B
    • Linzess/Constella: $954.00 M
    • Lumigan/Ganfort: $429.00 M
    • MAVYRET: $1.31 B
    • Other Aesthetics: $1.28 B
    • Other Eye Care: $847.00 M
    • Other Neuroscience: $338.00 M
    • Other Products: $3.03 B
    • Ozurdex: $494.00 M
    • Qulipta: $658.00 M
    • Restasis: $224.00 M
    • RINVOQ: $5.97 B
    • SKYRIZI: $11.72 B
    • Ubrelvy: $1.01 B
    • VENCLEXTA: $2.58 B
    • Vraylar: $3.27 B

    Learn more about AbbVie’s Revenue by Geography

    Check out competitors to AbbVie in a side-by-side comparison.

    Explore additional financial metrics for AbbVie.

    Continue reading...

    The above chart shows AbbVie's revenue percentage share by segment (products and services).

    In fiscal year 2022, AbbVie's revenue by segment is as follows:

    • Alphagan/Combigan generated $346.00 M in revenue, representing 0.62% of its total revenue.
    • Botox Cosmetic generated $2.62 B in revenue, representing 4.67% of its total revenue.
    • Botox Therapeutic generated $2.72 B in revenue, representing 4.86% of its total revenue.
    • Duodopa generated $458.00 M in revenue, representing 0.82% of its total revenue.
    • H U M I R A generated $21.24 B in revenue, representing 37.97% of its total revenue.
    • Imbruvica generated $4.57 B in revenue, representing 8.17% of its total revenue.
    • Juvederm Collection generated $1.43 B in revenue, representing 2.55% of its total revenue.
    • Linzess/Constella generated $1.04 B in revenue, representing 1.85% of its total revenue.
    • Lumigan/Ganfort generated $514.00 M in revenue, representing 0.92% of its total revenue.
    • MAVYRET generated $1.54 B in revenue, representing 2.75% of its total revenue.
    • Other Aesthetics generated $1.29 B in revenue, representing 2.31% of its total revenue.
    • Other Eye Care generated $1.18 B in revenue, representing 2.1% of its total revenue.
    • Other Neuroscience generated $475.00 M in revenue, representing 0.85% of its total revenue.
    • Other Products generated $4.14 B in revenue, representing 7.4% of its total revenue.
    • Restasis generated $666.00 M in revenue, representing 1.19% of its total revenue.
    • RINVOQ generated $2.52 B in revenue, representing 4.51% of its total revenue.
    • SKYRIZI generated $5.17 B in revenue, representing 9.23% of its total revenue.
    • VENCLEXTA generated $2.01 B in revenue, representing 3.59% of its total revenue.
    • Vraylar generated $2.04 B in revenue, representing 3.64% of its total revenue.

    The biggest segment for AbbVie is the H U M I R A, which represents 37.97% of its total revenue.
    The smallest segment for AbbVie is the Alphagan/Combigan, which represents 0.62% of its total revenue.

    The above chart shows AbbVie's revenue percentage share by segment (products and services).

    In fiscal year 2023, AbbVie's revenue by segment is as follows:

    • Alphagan/Combigan generated $272.00 M in revenue, representing 0.51% of its total revenue.
    • Botox Cosmetic generated $2.68 B in revenue, representing 5.06% of its total revenue.
    • Botox Therapeutic generated $2.99 B in revenue, representing 5.64% of its total revenue.
    • Duodopa generated $468.00 M in revenue, representing 0.88% of its total revenue.
    • H U M I R A generated $14.40 B in revenue, representing 27.17% of its total revenue.
    • Imbruvica generated $3.60 B in revenue, representing 6.78% of its total revenue.
    • Juvederm Collection generated $1.38 B in revenue, representing 2.6% of its total revenue.
    • Linzess/Constella generated $1.11 B in revenue, representing 2.09% of its total revenue.
    • Lumigan/Ganfort generated $432.00 M in revenue, representing 0.81% of its total revenue.
    • MAVYRET generated $1.43 B in revenue, representing 2.7% of its total revenue.
    • Other Aesthetics generated $1.23 B in revenue, representing 2.33% of its total revenue.
    • Other Eye Care generated $803.00 M in revenue, representing 1.51% of its total revenue.
    • Other Neuroscience generated $276.00 M in revenue, representing 0.52% of its total revenue.
    • Other Products generated $3.04 B in revenue, representing 5.72% of its total revenue.
    • Ozurdex generated $472.00 M in revenue, representing 0.89% of its total revenue.
    • Qulipta generated $408.00 M in revenue, representing 0.77% of its total revenue.
    • Restasis generated $436.00 M in revenue, representing 0.82% of its total revenue.
    • RINVOQ generated $3.97 B in revenue, representing 7.49% of its total revenue.
    • SKYRIZI generated $7.76 B in revenue, representing 14.64% of its total revenue.
    • Ubrelvy generated $815.00 M in revenue, representing 1.54% of its total revenue.
    • VENCLEXTA generated $2.29 B in revenue, representing 4.32% of its total revenue.
    • Vraylar generated $2.76 B in revenue, representing 5.2% of its total revenue.

    The biggest segment for AbbVie is the H U M I R A, which represents 27.17% of its total revenue.
    The smallest segment for AbbVie is the Alphagan/Combigan, which represents 0.51% of its total revenue.

    The above chart shows AbbVie's revenue percentage share by segment (products and services).

    In fiscal year 2024, AbbVie's revenue by segment is as follows:

    • Alphagan/Combigan generated $248.00 M in revenue, representing 0.46% of its total revenue.
    • Botox Cosmetic generated $2.72 B in revenue, representing 5.01% of its total revenue.
    • Botox Therapeutic generated $3.28 B in revenue, representing 6.04% of its total revenue.
    • Duodopa generated $447.00 M in revenue, representing 0.82% of its total revenue.
    • H U M I R A generated $8.99 B in revenue, representing 16.55% of its total revenue.
    • Imbruvica generated $3.35 B in revenue, representing 6.16% of its total revenue.
    • Juvederm Collection generated $1.18 B in revenue, representing 2.17% of its total revenue.
    • Linzess/Constella generated $954.00 M in revenue, representing 1.76% of its total revenue.
    • Lumigan/Ganfort generated $429.00 M in revenue, representing 0.79% of its total revenue.
    • MAVYRET generated $1.31 B in revenue, representing 2.41% of its total revenue.
    • Other Aesthetics generated $1.28 B in revenue, representing 2.35% of its total revenue.
    • Other Eye Care generated $847.00 M in revenue, representing 1.56% of its total revenue.
    • Other Neuroscience generated $338.00 M in revenue, representing 0.62% of its total revenue.
    • Other Products generated $3.03 B in revenue, representing 5.58% of its total revenue.
    • Ozurdex generated $494.00 M in revenue, representing 0.91% of its total revenue.
    • Qulipta generated $658.00 M in revenue, representing 1.21% of its total revenue.
    • Restasis generated $224.00 M in revenue, representing 0.41% of its total revenue.
    • RINVOQ generated $5.97 B in revenue, representing 10.99% of its total revenue.
    • SKYRIZI generated $11.72 B in revenue, representing 21.57% of its total revenue.
    • Ubrelvy generated $1.01 B in revenue, representing 1.85% of its total revenue.
    • VENCLEXTA generated $2.58 B in revenue, representing 4.75% of its total revenue.
    • Vraylar generated $3.27 B in revenue, representing 6.01% of its total revenue.

    The biggest segment for AbbVie is the SKYRIZI, which represents 21.57% of its total revenue.
    The smallest segment for AbbVie is the Restasis, which represents 0.41% of its total revenue.
    Continue reading...

    Summary Table

    Products & Services (Percent Share) 2022 2023 2024
    VENCLEXTA 3.59% 4.32% 4.75%
    Imbruvica 8.17% 6.78% 6.16%
    Restasis 1.19% 0.82% 0.41%
    Other Eye Care 2.1% 1.51% 1.56%
    Lumigan/Ganfort 0.92% 0.81% 0.79%
    Alphagan/Combigan 0.62% 0.51% 0.46%
    Other Aesthetics 2.31% 2.33% 2.35%
    Juvederm Collection 2.55% 2.6% 2.17%
    Botox Cosmetic 4.67% 5.06% 5.01%
    MAVYRET 2.75% 2.7% 2.41%
    H U M I R A 37.97% 27.17% 16.55%
    RINVOQ 4.51% 7.49% 10.99%
    SKYRIZI 9.23% 14.64% 21.57%
    Botox Therapeutic 4.86% 5.64% 6.04%
    Duodopa 0.82% 0.88% 0.82%
    Other Neuroscience 0.85% 0.52% 0.62%
    Vraylar 3.64% 5.2% 6.01%
    Linzess/Constella 1.85% 2.09% 1.76%
    Other Products 7.4% 5.72% 5.58%
    Ubrelvy - 1.54% 1.85%
    Ozurdex - 0.89% 0.91%
    Qulipta - 0.77% 1.21%
    Total Revenue 100% 100% 100%

    The above chart shows the revenue trend of different segments of AbbVie.

    In fiscal year 2024, the SKYRIZI generated the most revenue ($11.72 B), and the Restasis generated the least revenue ($224.00 M).

    The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Alphagan/Combigan revenue decreased -8.82% ($24.00 M) from $272.00 M (in 2023) to $248.00 M (in 2024).
  • Botox Cosmetic revenue increased 1.42% ($38.00 M) from $2.68 B (in 2023) to $2.72 B (in 2024).
  • Botox Therapeutic revenue increased 9.76% ($292.00 M) from $2.99 B (in 2023) to $3.28 B (in 2024).
  • Duodopa revenue decreased -4.49% ($21.00 M) from $468.00 M (in 2023) to $447.00 M (in 2024).
  • H U M I R A revenue decreased -37.57% ($5.41 B) from $14.40 B (in 2023) to $8.99 B (in 2024).
  • Imbruvica revenue decreased -6.92% ($249.00 M) from $3.60 B (in 2023) to $3.35 B (in 2024).
  • Juvederm Collection revenue decreased -14.59% ($201.00 M) from $1.38 B (in 2023) to $1.18 B (in 2024).
  • Linzess/Constella revenue decreased -13.9% ($154.00 M) from $1.11 B (in 2023) to $954.00 M (in 2024).
  • Lumigan/Ganfort revenue decreased -0.69% ($3.00 M) from $432.00 M (in 2023) to $429.00 M (in 2024).
  • MAVYRET revenue decreased -8.32% ($119.00 M) from $1.43 B (in 2023) to $1.31 B (in 2024).
  • Other Aesthetics revenue increased 3.65% ($45.00 M) from $1.23 B (in 2023) to $1.28 B (in 2024).
  • Other Eye Care revenue increased 5.48% ($44.00 M) from $803.00 M (in 2023) to $847.00 M (in 2024).
  • Other Neuroscience revenue increased 22.46% ($62.00 M) from $276.00 M (in 2023) to $338.00 M (in 2024).
  • Other Products revenue decreased -0.1% ($3.00 M) from $3.04 B (in 2023) to $3.03 B (in 2024).
  • Ozurdex revenue increased 4.66% ($22.00 M) from $472.00 M (in 2023) to $494.00 M (in 2024).
  • Qulipta revenue increased 61.27% ($250.00 M) from $408.00 M (in 2023) to $658.00 M (in 2024).
  • Restasis revenue decreased -48.62% ($212.00 M) from $436.00 M (in 2023) to $224.00 M (in 2024).
  • RINVOQ revenue increased 50.44% ($2.00 B) from $3.97 B (in 2023) to $5.97 B (in 2024).
  • SKYRIZI revenue increased 50.95% ($3.96 B) from $7.76 B (in 2023) to $11.72 B (in 2024).
  • Ubrelvy revenue increased 23.44% ($191.00 M) from $815.00 M (in 2023) to $1.01 B (in 2024).
  • VENCLEXTA revenue increased 12.89% ($295.00 M) from $2.29 B (in 2023) to $2.58 B (in 2024).
  • Vraylar revenue increased 18.41% ($508.00 M) from $2.76 B (in 2023) to $3.27 B (in 2024).
    • Continue reading...

    Summary Table

    Products & Services 2022
    Value Change
    		2023
    Value Change
    		2024
    Value Change
    Alphagan/Combigan $346.00 M - $272.00 M
    21.39%
    		$248.00 M
    8.82%
    Botox Cosmetic $2.62 B - $2.68 B
    2.56%
    		$2.72 B
    1.42%
    Botox Therapeutic $2.72 B - $2.99 B
    10.00%
    		$3.28 B
    9.76%
    Duodopa $458.00 M - $468.00 M
    2.18%
    		$447.00 M
    4.49%
    H U M I R A $21.24 B - $14.40 B
    32.17%
    		$8.99 B
    37.57%
    Imbruvica $4.57 B - $3.60 B
    21.28%
    		$3.35 B
    6.92%
    Juvederm Collection $1.43 B - $1.38 B
    3.50%
    		$1.18 B
    14.59%
    Linzess/Constella $1.04 B - $1.11 B
    7.05%
    		$954.00 M
    13.90%
    Lumigan/Ganfort $514.00 M - $432.00 M
    15.95%
    		$429.00 M
    0.69%
    MAVYRET $1.54 B - $1.43 B
    7.20%
    		$1.31 B
    8.32%
    Other Aesthetics $1.29 B - $1.23 B
    4.34%
    		$1.28 B
    3.65%
    Other Eye Care $1.18 B - $803.00 M
    31.66%
    		$847.00 M
    5.48%
    Other Neuroscience $475.00 M - $276.00 M
    41.89%
    		$338.00 M
    22.46%
    Other Products $4.14 B - $3.04 B
    26.64%
    		$3.03 B
    0.10%
    Ozurdex - - $472.00 M - $494.00 M
    4.66%
    Qulipta - - $408.00 M - $658.00 M
    61.27%
    Restasis $666.00 M - $436.00 M
    34.53%
    		$224.00 M
    48.62%
    RINVOQ $2.52 B - $3.97 B
    57.38%
    		$5.97 B
    50.44%
    SKYRIZI $5.17 B - $7.76 B
    50.30%
    		$11.72 B
    50.95%
    Ubrelvy - - $815.00 M - $1.01 B
    23.44%
    VENCLEXTA $2.01 B - $2.29 B
    13.89%
    		$2.58 B
    12.89%
    Vraylar $2.04 B - $2.76 B
    35.38%
    		$3.27 B
    18.41%
    Total Revenue $55.94 B - $53.02 B
    5.22%
    		$54.33 B
    2.47%

    Related company

    Related

    Submit feedback to Bullfincher